Oncogene Proteins, Fusion
"Oncogene Proteins, Fusion" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The GENETIC TRANSLATION products of the fusion between an ONCOGENE and another gene. The latter may be of viral or cellular origin.
| Descriptor ID |
D015514
|
| MeSH Number(s) |
D12.776.602.500.500 D12.776.624.664.500
|
| Concept/Terms |
Oncogene Proteins, Fusion- Oncogene Proteins, Fusion
- Fusion Oncogene Proteins
- Proteins, Fusion Oncogene
- Oncogene Proteins, Chimeric
- Fusion Proteins, Oncogene
- Oncogene Fusion Proteins
- Proteins, Oncogene Fusion
- Chimeric Oncogene Proteins
- Proteins, Chimeric Oncogene
- Chimeric Proteins, Oncogene
- Oncogene Chimeric Proteins
- Proteins, Oncogene Chimeric
|
Below are MeSH descriptors whose meaning is more general than "Oncogene Proteins, Fusion".
Below are MeSH descriptors whose meaning is more specific than "Oncogene Proteins, Fusion".
This graph shows the total number of publications written about "Oncogene Proteins, Fusion" by people in this website by year, and whether "Oncogene Proteins, Fusion" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
| 2021 | 2 | 0 | 2 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oncogene Proteins, Fusion" by people in Profiles.
-
SIX1 and EWS/FLI1 co-regulate an anti-metastatic gene network in Ewing Sarcoma. Nat Commun. 2023 07 19; 14(1):4357.
-
ALK-positive?histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Blood. 2022 01 13; 139(2):256-280.
-
miR-130b and miR-128a are essential lineage-specific codrivers of t(4;11) MLL-AF4 acute leukemia. Blood. 2021 11 25; 138(21):2066-2092.
-
NUTM1-Rearranged Neoplasms-A Heterogeneous Group of Primitive Tumors with Expanding Spectrum of Histology and Molecular Alterations-An Updated Review. Curr Oncol. 2021 11 07; 28(6):4485-4503.
-
Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer. Ann Oncol. 2021 06; 32(6):817-819.
-
Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses. Cell Rep. 2019 10 15; 29(3):573-588.e7.
-
Myeloid Neoplasm With Eosinophilia and FIP1L1-PDGFRA Rearrangement Treated With Imatinib Mesylate: A Pediatric Case With Long-term Follow-up. J Pediatr Hematol Oncol. 2019 May; 41(4):334-335.
-
Detection of NRG1 Gene Fusions in Solid Tumors. Clin Cancer Res. 2019 Aug 15; 25(16):4966-4972.
-
NUTM1-rearranged neoplasia: a multi-institution experience yields novel fusion partners and expands the histologic spectrum. Mod Pathol. 2019 06; 32(6):764-773.
-
Molecular characterization of cancers with NTRK gene fusions. Mod Pathol. 2019 01; 32(1):147-153.